Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cytarabine
Drug ID BADD_D00560
Description A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Indications and Usage For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Marketing Status Prescription; Discontinued
ATC Code L01BC01
DrugBank ID DB00987
KEGG ID D00168
MeSH ID D003561
PubChem ID 6253
TTD Drug ID D07XSN
NDC Product Code 67457-452; 68083-343; 58623-0026; 68083-337; 67457-455; 71288-108; 61703-303; 70516-0163; 71288-109; 61703-319; 63323-120; 71288-169; 61703-305; 71288-168; 55512-0026; 61703-304; 12848-1003
Synonyms Cytarabine | Arabinosylcytosine | Cytosine Arabinoside | Arabinoside, Cytosine | Arabinofuranosylcytosine | Aracytidine | beta-Ara C | beta Ara C | Cytarabine Hydrochloride | Cytosar | Cytosar-U | Cytosar U | Ara-C | Ara C | Aracytine | Cytonal
Chemical Information
Molecular Formula C9H13N3O5
CAS Registry Number 147-94-4
SMILES C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.002931%Not Available
Pulmonary congestion24.03.08.001; 22.01.03.002; 02.05.02.0020.000139%Not Available
Pulmonary embolism22.06.02.001; 24.01.06.001--Not Available
Pulmonary haemorrhage24.07.01.016; 22.02.04.0030.000347%
Pulmonary oedema22.01.03.003; 02.05.02.0030.006660%
Pulse absent13.14.04.0050.001332%Not Available
Pyrexia08.05.02.0030.020780%
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.0030.001332%Not Available
Rash maculo-papular23.03.13.0040.001598%
Rash pruritic23.03.12.0020.001332%Not Available
Rectal haemorrhage07.12.03.001; 24.07.02.018--
Refractory anaemia with an excess of blasts16.01.04.006; 01.10.04.0060.000139%Not Available
Renal disorder20.01.02.002--Not Available
Renal failure20.01.03.0050.001529%Not Available
Respiratory acidosis22.02.02.004; 14.01.04.0020.001598%Not Available
Respiratory arrest22.02.01.0090.000278%Not Available
Respiratory disorder22.02.07.0020.002131%Not Available
Respiratory distress22.02.01.0120.004795%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.003475%
Reticulocyte count decreased13.01.05.009--Not Available
Rhinorrhoea22.02.05.0100.000533%
Salmonellosis11.02.19.0010.000533%Not Available
Second primary malignancy16.16.01.0140.001598%
Seizure17.12.03.001--
Sensory loss17.02.07.0070.000533%Not Available
Sepsis11.01.11.0030.006602%
Septic shock24.06.02.011; 11.01.11.0040.003614%Not Available
Shock24.06.02.0020.000533%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 17 Pages